▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3352 by analyst upside · 2026-11-13
HUM
Humana Inc.
Healthcare · Market Cap $53B · P/E 43.3x
ANALYST PRICE TARGET
+10.5%
implied upside to consensus target
Current Price $443.68
Consensus Target $490.08
Bull Target $596.0
Bear Target $280.0
Analysts Covering 24
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
12
Hold
8
Sell
1
52-Week Low $163.11
52-Week High $456.5
YTD Return +69.4%
FUNDAMENTALS
Market Cap $53B
P/E Ratio (TTM) 43.3x
Forward P/E 24.4x
EPS (TTM) $10.25
PEG Ratio 1.23
Dividend Yield 0.80%
Revenue (TTM) $154.2B
Profit Margin 0.8%
52-WEEK RANGE
52-Week Low $163.11
52-Week High $456.5
Current Price $443.68
Bear Target $280.0
Bull Target $596.0
● Now $443.68 ● Target $490.08
TRADING DATA
Avg Volume 1.3M
YTD Return +69.4%
Analyst Count 24
Consensus Buy
Upside to Target +10.5%
Last Updated 2026-11-13

ANALYST SUMMARY

Humana Inc. (HUM) is currently trading at $443.68 with a Wall Street consensus price target of $490.08, implying potential upside of 10.5% over the next 12 months. 24 analysts currently cover HUM, with a consensus rating of Buy - 62% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $596.0, while the most cautious has a target of $280.0.

HUM operates in the Healthcare sector with a market capitalisation of $53B. The stock is up 69.4% year-to-date and is currently trading near the upper end of its 52-week range of $163.11 – $456.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for HUM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Mizuho - Reiterated
Outperform → Outperform 2026-10-13 Building track record
UBS - Reiterated
Neutral → Neutral 2026-10-12 33% win rate (6 calls)
Truist Securities - Reiterated
Hold → Hold 2026-10-12 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-10-12 14% win rate (7 calls)
Raymond James ↑ Upgrade
Market Perform → Outperform 2026-10-12 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-10-09 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-10-09 14% win rate (7 calls)
Baird ↑ Upgrade
Neutral → Outperform 2026-10-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
55
out of 100
Coverage depth
25/30
Consensus clarity
16/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →